In all of these cases, CRISPR-mediated gene editing permanently restored dystrophin protein expression to alleviate the clinical symptoms of DMD, yielding a phenotype more closely resembling that of BMD. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.